
-
Adaptimmune Therapeutics NasdaqCM:ADAP Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Location: 60 Jubilee Avenue, Abingdon, OX14 4RX, United Kingdom | Website: https://www.adaptimmune.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
431.1M
Cash
59.56M
Avg Qtr Burn
-26.96M
Short % of Float
0.41%
Insider Ownership
0.30%
Institutional Own.
43.51%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TECELRA (afamitresgene autoleucel) Details Cancer, Synovialsarcoma | Approved Quarterly sales | |
Lete-cel (NY-ESO) Details Myxoid/Round cell liposarcoma, Sarcoma | BLA Submission | |
Uzatresgene autoleucel /uza-cel (ADP-A2M4CD8 )(MAGE A4) +/- nivolumab Details Cancer, Ovarian cancer | Phase 2 Update | |
TC-510 Details Cancer, Colorectal cancer , Ovarian cancer, Mesothelioma, Triple-negative breast cancer , Pancreatic cancer | Failed Discontinued | |
TC-110 (CD19) Details Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer | Failed Discontinued | |
Gavo-cel (TC-210) (Mesothelin) + nivolumab Details Solid tumor/s, Ovarian cancer, Cancer | Failed Discontinued | |
ADP-A2AFP Details Hepatocellular carcinoma, Cancer | Failed Discontinued | |
Uzatresgene autoleucel (uza-cel)(ADP-A2M4CD8) (MAGE A4) +/- nivolumab Details Head and neck cancer, Bladder cancer, Cancer, Solid tumor/s, Urothelial cancer | Failed Discontinued | |
afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s | Failed Discontinued |